IPP Bureau
FibroBiologics moves experimental psoriasis therapy into FDA review
By IPP Bureau - January 04, 2026
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Intelligent Bio Solutions taps Global MedTech giant Syrma Johari to scale production
By IPP Bureau - January 04, 2026
Syrma Johari is a globally recognised medical device engineering and manufacturing organisation
Mabwell’s groundbreaking anti-IL-11 antibody enters Phase II trials for pathological scarring
By IPP Bureau - January 04, 2026
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
FDA nod to first new motion sickness drug in 40 years
By IPP Bureau - January 04, 2026
The approval is supported by data from three pivotal clinical trials
Elanco scores USDA nod for new canine allergy drug Befrena
By IPP Bureau - January 04, 2026
Elanco expects Befrena to launch in the US in the first half of 2026
AstraZeneca elevates Vikram Chand as SVP, Head of R&D for Japan
By IPP Bureau - January 04, 2026
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
Manoj Joshi assumes charge of pharma secretary
By IPP Bureau - January 04, 2026
Before this appointment, he served as the Secretary in the Department of Land Resources, Ministry of Rural Development
Aarti Pharmalabs appoints Dr. Rakeshwar Bandichhor as Chief Scientific Officer
By IPP Bureau - January 04, 2026
Dr. Bandichhor brings nearly two decades of experience from Dr. Reddy's Laboratories
Indian Pharmacopoeia 2026 debuts with 121 new monographs targeting TB, diabetes, and cancer
By IPP Bureau - January 04, 2026
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
BioVarta 2025 puts the spotlight on translating biotech innovation into impact
By IPP Bureau - January 04, 2026
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
Zydus Group elevates Dr. Tushar Nahata to Vice President
By IPP Bureau - January 04, 2026
His professional background also includes key experience at Matrix Labs and Sun Pharma
Strides appoints Yajuvendra Singh M R as VP - Digital Transformation
By IPP Bureau - January 04, 2026
Singh previously served as Head of IT (Development and Manufacturing Services) at Syngene International Limited, Lead of IT Manufacturing at UPL, and AGM at The Hi-Tech Gears
Caplin Point Labs acquires 10 ANDAs, targets $473M US market
By IPP Bureau - January 03, 2026
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
Biotium launches GlycoLiner kits for fast & selective cell surface glycoprotein labelling
By IPP Bureau - January 03, 2026
Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols
CORONA Remedies posts double-digit growth in Q2, H1 FY26; PAT surges up to 35%
By IPP Bureau - January 03, 2026
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
